Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label single-arm study of human coagulation factor IX prophylaxis in previously treated children with moderate or severe hemophilia B
CTR20263443Phase 3Active
- Sponsor
- Shandong Taibang Biological Products
- Start
- Sep 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of human coagulation factor IX in hemophilia B (HB), sponsored by Shandong Taibang Biological Products. Started Sep 2026; status: active.
02
Drugs
human coagulation factor IX
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on CTR20263443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263443.